Tadalafil Therapy for Pulmonary Arterial Hypertension | Zendy

Nazzareno Galiè | Zendy; Bruce H. Brundage | Zendy; Hossein A. Ghofrani | Zendy; Ronald J. Oudiz | Zendy; Gérald Simonneau | Zendy; Zeenat Safdar | Zendy; Shelley Shapiro | Zendy; R. James White | Zendy; Melanie Chan | Zendy; Anthony Beardsworth | Zendy; Lyn R. Frumkin | Zendy; Robyn J. Barst | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tadalafil Therapy for Pulmonary Arterial Hypertension

Author(s) -

Nazzareno Galiè,

Bruce H. Brundage,

Hossein A. Ghofrani,

Ronald J. Oudiz,

Gérald Simonneau,

Zeenat Safdar,

Shelley Shapiro,

R. James White,

Melanie Chan,

Anthony Beardsworth,

Lyn R. Frumkin,

Robyn J. Barst

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.839274

Subject(s) - bosentan , tadalafil , medicine , endothelin receptor antagonist , placebo , confidence interval , endothelin receptor , pulmonary hypertension , sildenafil , cgmp specific phosphodiesterase type 5 , cardiology , anesthesia , pathology , receptor , alternative medicine

Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research